Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease-Reference-Cited by-同舟云学术

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease

Published:2022-02-14 Issue:2 Volume:5 Page:e2148355
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Zissimopoulos Julie¹²,Jacobson Mireille²³,Chen Yi²⁴,Borson Soo⁵

Affiliation:

1. Department of Health Policy and Management, Sol Price School of Public Policy, University of Southern California, Los Angeles

2. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles

3. Andrus School of Gerontology, University of Southern California, Los Angeles

4. Sol Price School of Public Policy, University of Southern California, Los Angeles

5. Department of Family Medicine, Keck School of Medicine, University of Southern California, Los Angeles

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2789007/zissimopoulos_2022_ld_210327_1644261208.43097.pdf

Reference6 articles.

1. Medicare and the shocking US Food and Drug administration approval of aducanumab: crisis or opportunity?;Crosson;JAMA Intern Med,2021

2. An introduction to the Understanding America Study internet panel.;Alattar;Soc Secur Bull,2018

3. Belluck, P. F.D.A. panel declines to endorse controversial Alzheimer’s drug. New York Times. Accessed September 17, 2021. https://www.nytimes.com/2020/11/06/health/aducanumab-alzheimers-drug-fda-panel.html

4. Hollmann? P, Lundebjerg? NE. Re: Food and Drug Administration’s review of Biogen’s drug aducanumab for Alzheimer’s disease. American Geriatrics Society. Accessed September 17, 2021. https://www.americangeriatrics.org/sites/default/files/inline-files/American%20Geriatrics%20Society_Letter%20to%20FDA%20Biogen%20Drug%20for%20Alzheimer%27s%20%28June%202021%29%20FINAL%20%281%29.pdf

5. Alzheimer's Association. Alzheimer's Association welcomes FDA approval of aducanumab. Accessed September 17, 2021. https://www.alz.org/news/2021/alzheimers-association-fda-approval-aducanumab

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural compounds from herbs and nutraceuticals as glycogen synthase kinase‐3β inhibitors in Alzheimer's disease treatment;CNS Neuroscience & Therapeutics;2024-08

2. Testing the ‘Faith Moves Mountains model’ to increase Alzheimer’s disease awareness, detection, and diagnosis among rural, racially, and ethnically diverse older adults;Aging & Mental Health;2023-12-21

3. Familiarity and Perceptions of Aducanumab in Caregivers of Hawaii Alzheimer’s Disease Patients: Results of a Telephone Survey;Cureus;2023-12-05

4. Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-11-15

5. Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial;Alzheimer's Research & Therapy;2022-11-04